{"id":"fexuprazan-injection-part-3","_chembl":{"chemblId":"CHEMBL6068511","moleculeType":"Small molecule","molecularWeight":"446.88"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"H+/K+-ATPase","explanation":"Fexuprazan is a potassium-competitive acid blocker that reversibly inhibits the gastric H+/K+-ATPase enzyme. This injectable formulation likely provides rapid acid suppression for patients unable to take oral medications, though the specific clinical rationale for this Part 3 formulation remains undisclosed in Phase 1 development.","oneSentence":"Expected to inhibit gastric acid secretion through potassium-competitive acid blocker (P-CAB) mechanism, similar to oral fexuprazan."},"_scrapedAt":"2026-03-28T06:02:58.517Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122974,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"pantoprazole","brand":"Protonix","company":"Pfizer","rationale":"Injectable proton pump inhibitor for parenteral acid suppression"},{"name":"esomeprazole","brand":"Nexium","company":"AstraZeneca","rationale":"Injectable PPI widely used for acute acid-related conditions"},{"name":"vonoprazan","brand":"Voquezna","company":"Phathom Pharmaceuticals","rationale":"Oral P-CAB competing in same mechanism class"}],"description":"Fexuprazan Injection_part 3 is an investigational formulation under development by Daewoong Pharmaceutical Co. LTD., currently in Phase 1 clinical trials. As a derivative of fexuprazan, it is expected to target acid-related gastrointestinal disorders, though specific indications for this injectable formulation have not been disclosed.","indications":{"approved":[{"status":"investigational","condition":"Acid-related gastrointestinal disorders","patientPopulation":"Adult patients requiring parenteral acid suppression"}]},"trialDetails":[{"nctId":"NCT06437951","phase":"PHASE1","title":"to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection","status":"NOT_YET_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2024-07","conditions":"Erosive Gastroesophageal Reflux Disease","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Fexuprazan Injection_part 3","genericName":"Fexuprazan Injection_part 3","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}